MENG-KUN TSAIFE-LIN LIN WUI-RUE LAICHIH-YUAN LEEREY-HENG HUPO-HUANG LEE2019-12-042019-12-0420090391-3988https://www.scopus.com/inward/record.uri?eid=2-s2.0-70149087539&doi=10.1177%2f039139880903200608&partnerID=40&md5=c900bf058379d9177f95711348f2a06chttps://scholars.lib.ntu.edu.tw/handle/123456789/434632Background: Chronic nephrotoxicity of calcineurin inhibitors (CNIS) causes irreversible renal dysfunction and shortens renal transplant survival. We conducted a retrospective cohort study to test a hypothesis that de novo Cni minimization combined with sirolimus (SRL) improves graft survival in renal transplant patients without antibody induction therapy. Methods: Between october 2000 and august 2007, we performed 100 cases of renal transplantation with de novo CNI (either cyclosporine or tacrolimus) minimization combined with sirolimus (SRL group). The initial target trough levels were 100-200 ng/ml for cyclosporine (CsA) and 4-8 ng/mL for tacrolimus (TAC). sRL was given at a loading dose of 6 mg plus 2 mg/day for maintenance. The results for the sRL group were compared to those of 104 transplant recipients given standard CNI- (CSA- or TAC-) based immunosuppressive regimens including mycophenolate mofetil (MMF group) during the same period. Results: The 1-year rejection-free survival (94.8%) and 5-year graft survival (87.7%) rates of the sRL group were significantly better than those of the MMF group (85.5% and 75.2%, respectively). on univariate analyses, 6-month estimated glomerular filtration rate (eGFR), acute rejection and sRL therapy had a significant impact on graft survival, and sRL therapy and tacrolimus therapy had a significant impact on rejection-free survival. Multivariate analyses identified 6-month eGFR as the only prognostic factor for graft survival. acute rejection and sRL therapy were significant for post-transplant renal function. Conclusions: De novo CNI minimization combined with SRL could decrease acute rejection and improve renal function and graft survival after renal transplantation without the use of antibody induction therapy. ? Wichtig Editore, 2009.[SDGs]SDG3Drug products; Grafting (chemical); Grafts; Multivariant analysis; Acute rejection; Calcineurin inhibitors; CN: minimization; Graft survival; Induction therapy; Kidney transplantation; Minimisation; Renal transplants; Sirolimus; Tacrolimus; Antibodies; azathioprine; calcineurin inhibitor; cholesterol; corticosteroid; cyclosporin A; immunoglobulin; insulin; liver enzyme; methylprednisolone; mycophenolic acid; mycophenolic acid 2 morpholinoethyl ester; oral antidiabetic agent; prednisolone; rapamycin; rituximab; tacrolimus; triacylglycerol; acute graft rejection; adult; arthralgia; article; clinical trial; cohort analysis; colon cancer; controlled clinical trial; controlled study; cytopenia; deep vein thrombosis; diabetes mellitus; diarrhea; disease free survival; drug blood level; drug dose reduction; drug efficacy; drug substitution; drug withdrawal; female; glomerulopathy; glomerulus filtration rate; graft survival; human; hyperlipidemia; incisional hernia; infection; kidney allograft; kidney disease; kidney function; kidney graft rejection; kidney transplantation; leg swelling; leukocyte count; leukopenia; liver toxicity; loading drug dose; low drug dose; lung hemorrhage; lymphocele; lymphoproliferative disease; major clinical study; male; prognosis; retrospective study; side effect; survival rate; survival time; transitional cell carcinoma; triacylglycerol blood level; urine incontinence; uterine cervix carcinomajournal article10.1177/039139880903200608196701892-s2.0-70149087539